Specializing in oncology investments, the manager has a proven track record of backing over 25 early-stage biotech companies across North America and Europe. Focused on innovative therapies, they emphasize a hands-on approach that fosters strong collaboration with portfolio companies. Known for strategic exits, the manager has achieved multiple successful liquidity events. With a reputation for identifying breakthrough technologies, their investment style combines rigorous due diligence with a forward-looking market perspective.